The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, ...

The new Moderna COVID vaccine, mNexspike, is approved for adults 65 and older and people 12 to 64 with an underlying medical ...

Moderna (MRNA), with its widely used COVID-19 vaccine, rose to prominence during the global pandemic. The stock soared an eye ...

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal government.

She explains how the company’s new corporate branding aims to underscore its commitment to trust and transparency in its partnerships with pharma.

Moderna's experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial ...

Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate ...

A bipartisan group of senators is working to draft legislation to reform a fast-growing hospital drug discount program designed to help low-income patients.